RESEACHImmune cell activation by combining with a flu shot.
The number of immune cells and antibody titers were increased in healthy adults after flu shot.
AHCC® administration to healthy adults for 3 weeks starting from the day of infulenza vaccination increased the
number of NK cells and cytotoxic T cells in the AHCC® group compared to the control group. In addition,
a significant rise in antibody titers (the amount and strength of antibodies) were observed in the AHCC® group.
These findings suggest that AHCC® intake could support the effect of influenza vaccination to prevent infection and aggravation.
Brooke E Roman et al., Nutrition Research, 33(1): 12-17 (2013)
Design: A randomized, controlled trial
Subject: 29 healthy volunteers
Groups: Influenza vaccination + AHCC® (AHCC®: n=14) and influenza vaccination alone (control: n=15)
Dose and period: 3.0 g/day for 3 weeks from the day of vaccination
Endpoints: Comparison of lymphocyte populations measured by flow cytometry and levels of serum antibody titers and plasma cytokines between day 0 and 3 weeks after
The AHCC® group increased NK-T cells and CD8+ T cells compared to the control group. Furthermore, AHCC®
supplementation significantly improved the protective antibody titer level to influenza B, indicating that
AHCC® augments vaccine-associated effects.
Data are expressed as means±standard error of the mean (SEM).
RESEACHOpportunistic infections associated with weakened immune system
AHCC® may support to prevent opportunistic infections and keep good health.
Methicillin-resistant Staphylococcus aureus (MRSA), a pathogen that may cause fatal opportunistic infection, was inoculated to immunosuppressed mice. After 4 weeks of AHCC® administration, the survival duration was significantly extended compared to the control group. As AHCC® also showed significant extension of the survival duration with other similar studies with Candida albicans or Pseudomonas aeruginosa, AHCC® is expected to help maintain a good condition even under compromised immune system.
Hiroko Ishibashi et al., Yakugaku Zasshi, 120(8): 715-719 (2000)
Non-clinical study (in vivo)
Animal: 4-week-old male ICR/SPF mice immunosuppressed by cyclophosphamide treatment
Groups: AHCC® (n=8) and control (n=9)
Dose and period: 500 mg/kg/day for 4 weeks
Evaluation: Survival duration after inoculation of methicillin-resistant Staphylococcus aureus (MRSA)
It was revealed that AHCC® significantly prolonged survival time and alleviated severity of opportunistic infections.
AHCC® is expected to stimulate protective immune response against various viral infections.
AHCC® has been studied about its efficacy for different types of bacterial and viral infectious diseases
including West Nile virus, influenza virus, hepatitis virus, and human papillomavirus (HPV).
In those studies, it is shown that NK (natural killer) cell, NK-T (natural killer T) cell, and γ δ T (gamma delta T) cell, are modulated and activated by AHCC® intake, so the effect of AHCC® on infectious diseases is considered to be an activation of host innate immunity which is responsible for an initial defense of the immune system. In addition, such immunomodulatory effects of AHCC® are studied and reported in other types of diseases.
Therefore, although the efficacy of AHCC® against coronavirus has not been specifically evaluated, AHCC® is expected to be effective in prevention and clearance of various infectious pathogens including coronavirus, by modulating and optimizing host immune functions.
Francesco Di Pierro et al., Minerva Gastroenterol Dietol, 66(2): 172-176 (2020)
Comprehensive evaluation on past studies regarding the immunomodulative effect and preventive effect of AHCC® against various viral infections suggested that AHCC® could prevent infection with human pathogenic coronaviruses including SARS-CoV-2 and increase in severity of the infection.